CL2012001102A1 - Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas. - Google Patents

Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas.

Info

Publication number
CL2012001102A1
CL2012001102A1 CL2012001102A CL2012001102A CL2012001102A1 CL 2012001102 A1 CL2012001102 A1 CL 2012001102A1 CL 2012001102 A CL2012001102 A CL 2012001102A CL 2012001102 A CL2012001102 A CL 2012001102A CL 2012001102 A1 CL2012001102 A1 CL 2012001102A1
Authority
CL
Chile
Prior art keywords
hexahydrocyclopenta
pyrrol
benzamide
poisoning
cerebral
Prior art date
Application number
CL2012001102A
Other languages
English (en)
Inventor
Caryn Trocme-Thibierge
Aurore Sors
Florence Keime-Guibert
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44351420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001102(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2012001102A1 publication Critical patent/CL2012001102A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2012001102A 2011-05-02 2012-04-27 Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas. CL2012001102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101347A FR2974729B1 (fr) 2011-05-02 2011-05-02 Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
CL2012001102A1 true CL2012001102A1 (es) 2014-06-20

Family

ID=44351420

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001102A CL2012001102A1 (es) 2011-05-02 2012-04-27 Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas.

Country Status (28)

Country Link
US (3) US8940785B2 (es)
EP (1) EP2520296A1 (es)
JP (1) JP2012232978A (es)
KR (2) KR101493757B1 (es)
CN (1) CN102764439A (es)
AP (1) AP3104A (es)
AR (1) AR086146A1 (es)
BR (1) BR102012010244A2 (es)
CA (1) CA2775624A1 (es)
CL (1) CL2012001102A1 (es)
CR (1) CR20120192A (es)
CU (1) CU20120064A7 (es)
EA (1) EA020987B1 (es)
EC (1) ECSP12011862A (es)
FR (1) FR2974729B1 (es)
GE (1) GEP20146076B (es)
MA (1) MA34776B1 (es)
MX (1) MX2012005103A (es)
NI (1) NI201200070A (es)
PE (1) PE20130016A1 (es)
RU (1) RU2013153140A (es)
SG (2) SG185240A1 (es)
SV (1) SV2012004203A (es)
TN (1) TN2012000177A1 (es)
TW (1) TW201247200A (es)
UY (1) UY34050A (es)
WO (1) WO2012150412A1 (es)
ZA (1) ZA201203163B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2976285B1 (fr) * 2011-06-08 2013-05-24 Servier Lab Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent
SG11201900681SA (en) * 2016-08-18 2019-02-27 Suven Life Sciences Ltd Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
WO2018033848A1 (en) * 2016-08-18 2018-02-22 Suven Life Sciences Limited Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist
CN108371660B (zh) * 2017-12-14 2020-03-10 五邑大学 一种四氢环戊二烯并吡咯化合物及其衍生物的用途
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
CA3139082A1 (en) * 2019-05-21 2020-11-26 LA PharmaTech Inc. Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BRPI0510365A (pt) * 2004-04-28 2007-11-06 Takeda Pharmaceutical composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
US20100234389A1 (en) * 2007-10-10 2010-09-16 Takeda Pharmaceutical Company Limited Amide compound
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CU20120064A7 (es) 2013-12-27
SG2014010904A (en) 2014-05-29
US20120283244A1 (en) 2012-11-08
GEP20146076B (en) 2014-04-10
US20150080378A1 (en) 2015-03-19
MX2012005103A (es) 2013-06-05
US8940785B2 (en) 2015-01-27
US20150080379A1 (en) 2015-03-19
JP2012232978A (ja) 2012-11-29
CN102764439A (zh) 2012-11-07
KR20140051200A (ko) 2014-04-30
EA020987B1 (ru) 2015-03-31
PE20130016A1 (es) 2013-01-26
NZ599633A (en) 2014-02-28
NI201200070A (es) 2012-11-09
TW201247200A (en) 2012-12-01
UY34050A (es) 2012-11-30
CR20120192A (es) 2012-12-06
RU2013153140A (ru) 2015-06-10
EA201200527A1 (ru) 2012-12-28
EP2520296A1 (fr) 2012-11-07
TN2012000177A1 (fr) 2013-12-12
KR101493757B1 (ko) 2015-02-16
ECSP12011862A (es) 2012-07-31
KR20130130238A (ko) 2013-12-02
SG185240A1 (en) 2012-11-29
AP3104A (en) 2015-01-31
WO2012150412A1 (fr) 2012-11-08
FR2974729A1 (fr) 2012-11-09
SV2012004203A (es) 2012-08-23
CA2775624A1 (fr) 2012-11-02
ZA201203163B (en) 2013-01-30
FR2974729B1 (fr) 2013-04-19
AR086146A1 (es) 2013-11-20
AP2012006232A0 (en) 2012-04-30
BR102012010244A2 (pt) 2013-06-18
MA34776B1 (fr) 2014-01-02

Similar Documents

Publication Publication Date Title
CL2012001102A1 (es) Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida de formula i definida o una de sus sales y un inhibidor de la acetilcolinesterasa ; composicion farmaceutica; uso para trarar trastornos cognitivos asociados a envegecimiento cerebral y las enfermedades neurodegenerativas.
CR20130410A (es) Compuestos y composiciones como inhibidores de la trk
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
CL2013003638A1 (es) Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas.
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
ECSP14013153A (es) Compuestos inhibidores de metaloenzimas
BR112013033098B8 (pt) inibidores de glicosidade seletivos e usos dos mesmos
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
BRPI0919004A2 (pt) composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
CL2014002334A1 (es) Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
CR20140554A (es) Compuestos de acido dimetil-benzoico
HRP20182043T8 (hr) Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
CR20140553A (es) Compuestos de fenoxietil piperidina
BR112015002275A2 (pt) processos e intermediários para a preparação de inibidores da integrase
CL2014002978A1 (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa para el tratamiento de trastornos metabólicos
BRPI0919327A2 (pt) compostos ligados a enxofre para tratar doenças e distúrbios oftálmicos
BR112013030370A2 (pt) compostos de quinona para tratamento de doenças mediadas por ape1
SG11201401343YA (en) TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
DK3466437T3 (da) Middel til forebyggelse eller terapi af perinatale sygdomme for drøvtyggere
CO6801728A2 (es) Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis
ECSP12011941A (es) Procedimiento de síntesis y forma cristalina del hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida así como las composiciones farmacéuticas que la contienen